$TRUMP Argenx acquires biotech company Unnatural for $1.15 billion cepe
Argenx SE announced on Monday that it had acquired biotech company Unnatural Products for $550 million upfront, plus contingent value rights tied to development and regulatory milestones, bringing the deal’s potential total value to approximately $1.15 billion.
The acquisition builds on a two-year, multi-target research collaboration between the companies. Unnatural Products is developing large cyclic peptides for oral administration and will continue operating from its headquarters in Santa Cruz, California, joining Argenx’s global research network once the deal is completed.
The deal is expected to close by the end of this year, subject to customary closing conditions.
$XAU
#NvidiaInvestigatesAfterHuang’sAffairApology #BitcoinFiveWeeklyLosses #EthereumSpotETFsPost$365MWeeklyOutflow #TradFiForBeginners
Argenx SE announced on Monday that it had acquired biotech company Unnatural Products for $550 million upfront, plus contingent value rights tied to development and regulatory milestones, bringing the deal’s potential total value to approximately $1.15 billion.
The acquisition builds on a two-year, multi-target research collaboration between the companies. Unnatural Products is developing large cyclic peptides for oral administration and will continue operating from its headquarters in Santa Cruz, California, joining Argenx’s global research network once the deal is completed.
The deal is expected to close by the end of this year, subject to customary closing conditions.
$XAU
#NvidiaInvestigatesAfterHuang’sAffairApology #BitcoinFiveWeeklyLosses #EthereumSpotETFsPost$365MWeeklyOutflow #TradFiForBeginners
